Efficacy and Tolerability of Deucravacitinib in the Management of Palmoplantar Pustulosis

Summary

The goal of this clinical trial is to investigate the efficacy and safety of Deucravacitinib in patients with moderate-to-severe palmoplantar pustulosis. Approximately 25 subjects will be included in the study and receive Deucravacitinib 6mg per day for four months. This study will begin June 2025 and is expected to last 14 months.

Timeline

Start

2025-06-20

Primary completion

2025-11-30

Completion

2025-12-01

Drugs

Indications